2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer

Topline results from the Phase 3 TALAPRO-3 study indicate that combining the PARP inhibitor talazoparib (Talzenna) with enzalutamide (Xtandi) significantly improves outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). The trial focused on patients with homologous recombination repair (HRR) gene mutations, a subgroup increasingly recognized as especially relevant for precision treatment strategies. The study met its primary endpoint by demonstrating a statistically significant increase in radiographic progression-free survival (rPFS). The combination also markedly exceeded the pre-specified hazard ratio of 0.63, suggesting a robust benefit when targeted therapy is introduced earlier in the disease course. For the practicing oncologist, these findings may support a shift toward more personalized treatment in the front-line setting. Early analysis also showed a strong trend toward improved overall survival (OS), which remains one of the most meaningful outcomes in advanced prostate cancer. Pfizer has said it plans to submit these findings to regulatory authorities globally. That could position the regimen as a potential new standard of care for this biomarker-defined population. Clinicians should still keep treatment-emergent anemia in mind as an important safety consideration.

Apixaban significantly reduces bleeding risk vs rivaroxaban in acute VTE

Results from the Phase 4 COBRRA trial, published in the March 19, 2026 issue of the New England Journal of Medicine, help clarify a long-standing debate over the safety of direct oral anticoagulants (DOACs). Among 2,760 patients with acute venous thromboembolism (VTE), those randomized to apixaban experienced a 3.3% rate of clinically relevant bleeding compared with 7.1% in the rivaroxaban group. That translated to a 54% relative reduction in bleeding risk. Importantly, the improved safety profile did not appear to come at the expense of efficacy. Recurrent VTE rates were nearly identical between the two treatment groups. For the practicing hematologist or internist, apixaban now appears to be a safer first-line option during the high-risk first three months of treatment. The study authors suggest that the difference may relate to rivaroxaban’s intensive initial dosing strategy of 15 mg twice daily for the first 21 days. These data may meaningfully influence anticoagulant selection in routine clinical practice. They also offer a more evidence-based framework for choosing between two commonly used oral agents.

Lilly’s retatrutide achieves 16.8% weight loss in Phase 3 diabetes trial

Eli Lilly announced on March 19, 2026, that its investigational triple-agonist retatrutide met all primary and key secondary endpoints in the TRANSCEND-T2D-1 Phase 3 trial. The therapy targets GIP, GLP-1, and glucagon receptors, making it one of the most closely watched next-generation incretin candidates in development. In the study, the drug produced a mean weight loss of 16.8% and an A1C reduction of 2.0% over 40 weeks. Participants receiving the 12 mg dose lost an average of 36.6 pounds. Those figures place retatrutide ahead of many current dual-agonist benchmarks in patients with type 2 diabetes. For endocrinologists, this suggests a possible future option for more intensive metabolic treatment. Lilly is also studying the drug broadly across cardiometabolic indications, reinforcing its long-term commercial and clinical significance. Ongoing development details can also be followed through clinical trial tracking. Another notable finding was that weight loss continued through the end of treatment without reaching a plateau.

FDA warns Novo Nordisk over serious safety reporting violations

The FDA has issued a warning letter to Novo Nordisk, alleging that the company failed to comply with mandatory postmarketing adverse drug experience reporting requirements. According to the agency, inspectors found that several serious events were not reported within the legally required timeframe. The FDA emphasized that this does not necessarily mean the drugs caused those reported events. Even so, delays in safety reporting can interfere with the agency’s ability to evaluate real-world risks quickly and effectively. That is especially important for high-profile therapies used by large patient populations. The agency noted that timely safety reporting is essential to ongoing pharmacovigilance. For clinicians, the letter is a reminder to remain attentive to emerging safety concerns even when medications are widely prescribed and commercially successful. It also reinforces the importance of independent adverse event reporting when suspicious reactions arise in practice. In the context of rapidly expanding GLP-1 use, regulatory transparency remains particularly important.

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.